Diagnostics company expands flow cytometry line
Global life sciences provider acquires antibody cocktails to target routine clinical analyses.
International diagnostics company, Beckman Coulter Life Sciences (CA, USA), has recently announced its acquisition of the flow cytometry business assets of ReaMetrix India Pvt. Ltd (Karnataka, India). Beckman Coulter Life Sciences will now have access to antibody cocktails for use in HIV monitoring and clinical research that are multi-color, single-dose and temperature stable. The reagents acquired from ReaMetrix will simplify the sample preparation and provide reagent combinations to further cytometry laboratories.
According to Mario Koksch, Vice President and General Manager of the Cytometry Business Unit at Beckman Coulter Life Sciences. “This acquisition provides both immediate opportunity and long-term value,” He continued, “The simplification of customer workflows will be dramatic. We’ll be able to offer customers an extended line of market leading technology while expanding our reach within two key segments for flow cytometry — HIV monitoring and clinical research.”
ReaMetrix products are some of the first dry temperature-stable flow cytometry reagents approved for in vitro diagnostic use in Europe. Bala Manian, Chief Executive Officer of ReaMetrix India Pvt. Ltd, said of the acquisition, “Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation. The development of room temperature stable unitized flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world.”
Source: Beckman Coulter Life Sciences acquires assets of ReaMetrix India Pvt. Ltd.
